List view / Grid view
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months over fulvestrant alone.
According to a new report, the orphan drug market is growing more than twice as fast as the non-orphan market and, by 2026, orphan drug sales will account for 20 percent of all prescription drug sales.
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
Investigational drug Lambda reduced risk of COVID-19-related death in one of the largest studies of its kind to date.
AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
In this article by IMA, discover how IMAGO software installed on rotary tablet presses supports scientists during tablet manufacturing, providing critical insights into powders.
Following his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
EMA will establish the DARWIN EU® Coordination Centre to develop and manage a network of real-world healthcare data sources across the EU.
The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
Population pharmaceutical quality assessment could be used to improve the quality consistency of generic drugs, suggests study.
Application note: Comprehensive fractionation of herbal medicine components by PDA-ELSD-triggered preparative LC
This article introduces a comprehensive fractionation method for both UV absorbing and non-UV absorbing compounds.
Application note: Taxonomic traceability for bacterial and fungal entries in Accugenix® reference databases
When you are reviewing bacterial and fungal isolates, do you appreciate that the names given to these organisms are regulated?